Is there a role of PSMA-PET in focal therapy planning and follow-up? (2025)

1. Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, et al. Oncological results and cancer control definition in focal therapy for Prostate Cancer: a systematic review. Prostate Cancer Prostatic Dis. 2024;27:623–34.

2. Nicoletti R, Alberti A, Castellani D, Yee CH, Zhang K, Poon DMC, et al. Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs). Prostate Cancer Prostatic Dis. 2024;27:614–22.

3. Ahmed HU. The index lesion and the origin of prostate cancer. N Engl J Med. 2009;361:1704–6.

   Article PubMed CAS Google Scholar

4. Ahmed HU, Pendse D, Illing R, Allen C, van der Meulen JH, Emberton M. Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pr Oncol. 2007;4:632–42.

   Article Google Scholar

5. Huber PM, Afzal N, Arya M, Boxler S, Dudderidge T, Emberton M, et al. Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high intensity focused ultrasound. J Urol. 2020;203:734–42.

   Article PubMed Google Scholar

6. Mattlet A, Limani K, Alexandre P, Hawaux E, Abou Zahr R, Aoun F, et al. External validation of biochemical recurrence definition to predict oncologic outcomes following focal therapy for localized prostate cancer using high intensity focused ultrasound. Prostate. 2023;83:1564–71.

   Article PubMed CAS Google Scholar

7. Blana A, Brown SCW, Chaussy C, Conti GN, Eastham JA, Ganzer R, et al. High‐intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int. 2009;104:1058–62.

   Article PubMed CAS Google Scholar

8. Lebastchi AH, George AK, Polascik TJ, Coleman J, de la Rosette J, Turkbey B, et al. Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus. Eur Urol. 2020;78:371–8.

   Article PubMed PubMed Central Google Scholar

9. Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz L, et al. Surveillance after prostate focal therapy. World J Urol. 2019;37:397–407.

   Article PubMed Google Scholar

10. Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, et al. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol. 2015;33:1503–9.

    Article PubMed PubMed Central CAS Google Scholar

11. Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, et al. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Lancet Oncol. 2017;18:181–91.

    Article PubMed CAS Google Scholar

12. Rouvière O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mège-Lechevallier F, et al. Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radio. 2010;20:48–55.

    Article Google Scholar

13. Rosenkrantz AB, Taneja SS. Radiologist, be aware: ten pitfalls that confound the interpretation of multiparametric prostate MRI. Am J Roentgenol. 2014;202:109–20.

    See Also

    First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer

    Article Google Scholar

14. Kirkham APS, Emberton M, Hoh IM, Illing RO, Freeman AA, Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology. 2008;246:833–44.

    Article PubMed Google Scholar

15. Rouvière O, Lyonnet D, Raudrant A, Colin-Pangaud C, Chapelon JY, Bouvier R, et al. MRI appearance of prostate following transrectal hifu ablation of localized cancer. Eur Urol. 2001;40:265–74.

    Article PubMed Google Scholar

16. Alvim R, Nagar K, Das S, Lebdai S, Wong N, Somma A, et al. Positron emission tomography/computed tomography with gallium-68–labeled prostate-specific membrane antigen detects relapse after vascular-targeted photodynamic therapy in a prostate cancer model. Eur Urol Focus. 2021;7:472–8.

    Article PubMed Google Scholar

17. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92.

    Article PubMed Google Scholar

18. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of 68 gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195:1436–43.

    Article PubMed Google Scholar

19. Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44:1622–35.

    Article PubMed CAS Google Scholar

20. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. 68 Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017;58:1617–23.

    Article PubMed CAS Google Scholar

21. N. Mottet, P. Cornford, R.C.N. van den Bergh, E. Briers, Expert Patient Advocate (European Prostate Cancer Coalition/Europa UOMO), D. Eberli, et al. EAU Guidelines on Prostate Cancer. 2023;

22. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

    Article PubMed PubMed Central Google Scholar

23. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;i4919.

24. Zamboglou C, Rischke HC, Meyer PT, Knobe S, Volgeova-Neher N, Kollefrath M, et al. Single fraction multimodal image guided focal salvage high-dose-rate brachytherapy for recurrent prostate cancer. J Contemp Brachytherapy. 2016;3:241–8.

    Article Google Scholar

25. Topoozian M, Calais J, Felker E, Sisk A, Gonzalez S, Lee SJ, et al. Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging. Urol Case Rep. 2023;50:102461.

    Article PubMed PubMed Central Google Scholar

26. Gielchinsky I, Lev-Cohain N. Focal irreversible electroporation for localized prostate cancer – oncological and safety outcomes using mpMRI and transperineal biopsy follow-up. Res Rep. Urol. 2023;ume 15:27–35.

    Google Scholar

27. Burger IA, Müller J, Donati OF, Ferraro DA, Messerli M, Kranzbühler B, et al. 68 Ga-PSMA-11 PET/MR detects local recurrence occult on mpMRI in prostate cancer patients after HIFU. J Nucl Med. 2019;60:1118–23.

    Article PubMed CAS Google Scholar

28. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, et al. Impact of 68 Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study. J Nucl Med. 2020;61:1153–60.

    Article PubMed PubMed Central CAS Google Scholar

29. Shin D, Yoon CE, Kwon HJ, Moon HW, Park YH, Cho HJ, et al. Irreversible electroporation for prostate cancer using PSMA PET-CT. Prostate Int. 2023;11:40–5.

    Article PubMed Google Scholar

30. Duan H, Ghanouni P, Daniel B, Rosenberg J, Davidzon GA, Aparici CM, et al. A Pilot Study of 68 Ga-PSMA11 and 68 Ga-RM2 PET/MRI for evaluation of prostate cancer response to high-intensity focused ultrasound therapy. J Nucl Med. 2023;64:592–7.

    Article PubMed CAS Google Scholar

31. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20.

    Article PubMed CAS Google Scholar

32. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, et al. 68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42:1284–94.

    Article PubMed Google Scholar

33. Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, et al. 68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard – Implications for focal radiotherapy planning in primary prostate cancer. Radiother Oncol. 2019;141:214–9.

    Article PubMed Google Scholar

34. Chiacchio G, Castellani D, Nedbal C, De Stefano V, Brocca C, Tramanzoli P, et al. Radiomics vs radiologist in prostate cancer. Results from a systematic review. World J Urol. 2023;41:709–24.

    Article PubMed Google Scholar

35. Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part i: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10–8.

    Article PubMed Google Scholar

36. Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

    Article PubMed CAS Google Scholar

37. Javitt MC, Kravtsov A, Keidar Z, Abadi S, Amiel GE. Multimodality image fusion with PSMA PET/CT and high-intensity focused ultrasound focal therapy for primary diagnosis and management of prostate cancer: a planned research initiative. Rambam Maimonides Med J. 2017;8:e0037.

    Article PubMed PubMed Central Google Scholar

38. Emmett LM, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63:1644–50.

39. Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682–9.

    Article PubMed CAS Google Scholar

40. Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun. 2019;40:86–91.

    Article PubMed Google Scholar

41. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol. 2016;70:829–36.

    Article PubMed CAS Google Scholar

42. Marra G, Shah TT, D’Agate D, Marquis A, Calleris G, Lunelli L, et al. The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol. Front Surg. 2022;9:900528.

43. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. 68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging. 2017;44:941–9.

    Article PubMed CAS Google Scholar

44. Kawada T, Yanagisawa T, Rajwa P, Sari Motlagh R, Mostafaei H, Quhal F, et al. Diagnostic performance of prostate-specific membrane antigen positron emission tomography–targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2022;5:390–400.

    Article PubMed Google Scholar

45. Wysock JS, Lepor H. Multi-parametric MRI imaging of the prostate—implications for focal therapy. Transl Androl Urol. 2017;6:453–63.

    Article PubMed PubMed Central Google Scholar

46. Fedorov A, Penzkofer T, Hirsch MS, Flood TA, Vangel MG, Masry P, et al. The role of pathology correlation approach in prostate cancer index lesion detection and quantitative analysis with multiparametric MRI. Acad Radio. 2015;22:548–55.

    Article Google Scholar

47. Patel P, Oto A. Magnetic resonance imaging of the prostate, including pre- and postinterventions. Semin Interv Radio. 2016;33:186–95.

    Article Google Scholar

48. Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, et al. Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy. Eur Urol Oncol. 2023;6:629–34.

    Article PubMed Google Scholar

49. Lotte R, Lafourcade A, Mozer P, Conort P, Barret E, Comperat E, et al. Multiparametric MRI for suspected recurrent prostate cancer after HIFU:Is DCE still needed? Eur Radio. 2018;28:3760–9.

    Article Google Scholar

50. Deivasigamani S, Kotamarti S, Rastinehad AR, Salas RS, de la Rosette JJMCH, Lepor H, et al. Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement. Eur Urol. 2023;84:547–60.

    Article PubMed Google Scholar

51. Rodríguez‐Sánchez L, Reiter R, Rodríguez A, Emberton M, de Reijke T, Compérat EM, et al. The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer. BJU Int. 2024;134:50–3.

    Article PubMed Google Scholar

52. Beyer T, Czernin J, Freudenberg L, Giesel F, Hacker M, Hicks RJ, et al. A 2022 international survey on the status of prostate cancer theranostics. J Nucl Med. 2023;64:47–53.

    Article PubMed CAS Google Scholar

53. Freudenberg LS, Hicks RJ, Beyer T. An international survey on clinical reporting of PET/CT examinations: a starting point for cross-specialty engagement. J Nucl Med. 2019;60:480–5.

    Article PubMed Google Scholar

54. Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011;52:303–10.

    Article PubMed Google Scholar

Download references